Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...

In the United States, ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is investigational.

Fintel reports that on February 28, 2025, JP Morgan downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) had its price target reduced by research analysts at Ascendiant Capital Markets from $33.00 to $24.00 in a research note issued to investors on ...

Fintel reports that on February 27, 2025, HC Wainwright & Co. downgraded their outlook for LAVA Therapeutics N.V.

On-demand video webcast now available here ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval ...

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing novel therapies for hematopoietic stem cell transplantation and mast cell-mediated diseases.

The new Outlook comes bundled with the recent versions of monthly security updates. Since it’s the only free mail client on ...

2 月 28 日消息，微软更新支持文档，承认 Windows 11 24H2 用户安装 1 月可选更新或者 2 月累积更新后， 会导致经典版 Outlook 出现无法拖拽的问题。 微软表示用户安装 2025 年 1 月的非安全更新（KB5050094 ...

On Tuesday, H.C. Wainwright analyst Douglas Tsao revised the price target for Outlook Therapeutics Inc. (NASDAQ:OTLK), a small-cap biotech with a market capitalization of ...